Methods of treating neurodegenerative conditions
View Patent ↗The present disclosure is directed to adeno-associated viral vector monoclonal antibody constructs and compositions thereof, methods of improving locomotor function after spinal cord injury, methods of treating neurodegenerative diseases.
1. An adeno-associated viral vector monoclonal antibody construct AAV10-NG2Ab of SEQ ID NO. 1.
2. A method of improving locomotor function after spinal cord injury in a subject in need thereof comprising the administration of AAV10-NG2Ab and a pharmaceutically acceptable carrier.
3. The method of any claim 2 wherein said administration is intraspinal.
4. The method of claim 2 , wherein the AAV10-NG2Ab is administered in an amount of about 1.0×10 12 to about 8.0×10 12 GC/mL.
5. The method of claim 2 , wherein the AAV10-NG2Ab is administered in an amount of about 6.8×10 12 GC/mL.
6. The method of claim 2 , wherein the administration occurs for about one day to about ten weeks.
7. The method of claim 2 , wherein the administration occurs for about one week to about five weeks.
8. The method of claim 2 , wherein the administration occurs for about two weeks to about four weeks.
9. A composition, the composition comprising a therapeutically effective amount of AAV10-NG2Ab and at least one of a pharmaceutically acceptable carrier, diluent and excipient.
10. A method of improving locomotor function after spinal cord injury in a subject in need thereof comprising the administration of AAV10-NT3, AAV10-NG2Ab and a pharmaceutically acceptable carrier.